- Scancell Holdings has issued data showing patient immunologic response to cancer vaccine SCIB1 can be demonstrated through monitoring changes in the diversity of T cells found in the blood.

The collaboration between Scancell and ImmunID to predict SCIB1 responders using ImmunTraCkeR was announced in a press release on 30 July 2015.

"This initial data shows promise for the development of ImmunTraCkeR as a companion diagnostic for SCIB1 cancer immunotherapy" said Dr Nicolas Pasqual, Co-Founder & Chief Science Officer of ImmunID.

"The ability to identify patient responders to immuno-oncology treatments early is a key unmet clinical need which is likely to improve cancer patient outcomes."

Story provided by